Skip to main content
Clinical Trials/NCT02164526
NCT02164526
Unknown
Not Applicable

National, Prospective, Multicenter,Observational Registry Study on Pulmonary Hypertension Due to Left Heart Disease in China

Chinese Academy of Medical Sciences, Fuwai Hospital1 site in 1 country520 target enrollmentJanuary 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Pulmonary Hypertension Due to Left Heart Disease
Sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Enrollment
520
Locations
1
Primary Endpoint
All cause death
Last Updated
8 years ago

Overview

Brief Summary

Left heart disease is the main cause of pulmonary hypertension. With the advent of the aging society, chronic heart failure has become a global public health problem. Therefore the prevalence of pulmonary hypertension due to the left heart disease is increasing. However, there is no research on the prevalence of pulmonary hypertension due to the left heart disease in China. Therefore, the aim of the present study was to describe real-world outcome of Chinese patients with pulmonary hypertension due to the left heart disease and identify factors that may predict outcome. Our study will profile the demographics, clinical course, treatments, and outcomes of pulmonary hypertension due to the left heart disease in China.

Registry
clinicaltrials.gov
Start Date
January 2013
End Date
December 2018
Last Updated
8 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Responsible Party
Principal Investigator
Principal Investigator

Jianguo He

Director of Pulmonary vascular disease center

Chinese Academy of Medical Sciences, Fuwai Hospital

Eligibility Criteria

Inclusion Criteria

  • Pulmonary Hypertension due to left heart disease

Exclusion Criteria

  • Other forms of Pulmonary Hypertension
  • Heart failure due to valvular heart disease
  • Hypertrophic obstructive cardiomyopathy
  • Right ventricular outflow tract stenosis
  • Pericardial disease
  • Patients with chronic lung disease

Outcomes

Primary Outcomes

All cause death

Time Frame: up to 5 years

Study Sites (1)

Loading locations...

Similar Trials